New York, February 10, 2026, 14:01 EST — Regular session
- AbbVie shares up about 0.7% in afternoon trade, hovering near the day’s high
- BNP Paribas Exane raised its AbbVie price target to $213, kept a neutral rating
- Investors are watching delayed U.S. payrolls and inflation data this week for the next rate signal
AbbVie Inc shares rose 0.7% to $224.83 in early afternoon trade on Tuesday, staying close to the session high after a tight range. The stock traded between $223.00 and $225.78.
It’s not a big move, but AbbVie sits in a corner of the market where small shifts still matter. Investors keep coming back to the same question: can a large drugmaker hold growth steady when both competition and rate expectations keep moving.
U.S. stocks were mixed, with the Dow at a record high while the S&P 500 hovered around flat, as traders digested earnings and a weaker-than-expected retail sales print. “The retail sales data is indicating that maybe the economy wasn’t as strong as people expected,” said Charlie Ripley, vice president of portfolio management at Allianz Investment Management. 1
On the company side, BNP Paribas Exane lifted its price target on AbbVie to $213 from $203 and kept a “neutral” rating, MT Newswires reported on Monday. A price target is an analyst’s estimate of where a stock could trade over the next year. 2
AbbVie last week forecast 2026 adjusted profit of $14.37 to $14.57 per share, an earnings measure that strips out some one-time items, but shares fell after Rinvoq sales missed expectations. William Blair analyst Matt Phipps said investors “continue to have concerns about growing competition” for the company’s immunology franchise, including Johnson & Johnson’s Tremfya, while AbbVie CFO Scott Reents warned of “low-single-digit pricing headwinds” for Rinvoq and Skyrizi. 3
The BNP Paribas Exane target sits below the current share price, underlining how much of the near-term optimism is already priced in. That leaves less room for missteps, and more sensitivity to any new read on drug demand and pricing.
But the setup can flip quickly. Another stumble in Rinvoq growth, or sharper pricing pressure, would likely bring the focus back to how fast AbbVie can replace older cash flows.
Rate bets add another variable. Higher yields can cool demand for dividend-heavy drugmakers, while softer data tends to do the opposite, which is why pharma shares can track macro headlines even when company news is thin.
Next up are the delayed U.S. January payrolls report on Wednesday, Feb. 11, and the January CPI report on Friday, Feb. 13, both due at 8:30 a.m. ET after a brief government shutdown disrupted the calendar. 4
